A Safety and Tolerability Study of ABT-089 in Adults With Attention Deficit-Hyperactivity Disorder (ADHD)

Inclusion Criteria: * The subject was randomized into Study M06-855 and completed treatment in Periods 1 and 2 and the 2-week Extension Period * If female, subject must be either postmenopausal for at least 1 year, surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy), or practicing at least a method of birth control throughout the study * If female, the result of a pregnancy tests are negative * The subject is judged to be in generally good health Exclusion Criteria: * More than 7 days have elapsed since the last dose of study drug in Study M06-855 * The subject has taken any ADHD medication between the last dose of study drug in Study M06-855 and the first dose of study drug in the current study * The subject anticipates a move outside the geographic area